Windlas Biotech Ltd Stock Price Today (NSE: WINDLAS)
Fundamental Score
Windlas Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Windlas Biotech Ltd share price today is ₹817.00, down 1.47% on NSE/BSE as of 17 June 2026. Windlas Biotech Ltd (WINDLAS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.66K (Cr). The 52-week high for WINDLAS share price is ₹1097.90 and the 52-week low is ₹697.40. At a P/E ratio of 24.62x, WINDLAS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.76% and a debt-to-equity ratio of 0.06.
Windlas Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Windlas Biotech Ltd share price chart: -5.36% return over the past month. 52-week high ₹1097.90, 52-week low ₹697.40.
Windlas Biotech Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹813.10 | ₹828.95 | ₹797.15 | ₹812.30 | 46.93K (Cr) | |
| ₹833.10 | ₹848.00 | ₹810.85 | ₹813.10 | 36.37K (Cr) | |
| ₹812.60 | ₹852.55 | ₹812.60 | ₹833.10 | 75.11K (Cr) | |
| ₹821.35 | ₹833.00 | ₹790.00 | ₹819.70 | 1.93L (Cr) | |
| ₹793.95 | ₹830.00 | ₹784.10 | ₹822.85 | 84.47K (Cr) | |
| ₹804.95 | ₹805.00 | ₹770.15 | ₹785.25 | 1.16L (Cr) | |
| ₹784.10 | ₹796.90 | ₹752.00 | ₹789.95 | 2.00L (Cr) | |
| ₹807.95 | ₹814.80 | ₹779.00 | ₹782.35 | 58.54K (Cr) | |
| ₹768.90 | ₹802.85 | ₹760.20 | ₹798.05 | 87.34K (Cr) | |
| ₹779.00 | ₹784.95 | ₹761.00 | ₹767.40 | 32.28K (Cr) |
Windlas Biotech Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹833.10 | ₹848.00 | ₹797.15 | ₹812.30 | -2.50% | |
| ₹851.85 | ₹884.90 | ₹746.55 | ₹833.10 | -2.20% | |
| ₹747.95 | ₹898.80 | ₹743.20 | ₹851.85 | +13.89% | |
| ₹740.00 | ₹786.00 | ₹697.40 | ₹736.75 | -0.44% | |
| ₹818.80 | ₹928.50 | ₹746.00 | ₹755.00 | -7.79% | |
| ₹808.80 | ₹950.00 | ₹735.30 | ₹848.90 | +4.96% | |
| ₹788.00 | ₹818.00 | ₹731.75 | ₹795.05 | +0.89% | |
| ₹955.00 | ₹986.00 | ₹768.15 | ₹783.60 | -17.95% | |
| ₹905.00 | ₹963.95 | ₹904.50 | ₹945.50 | +4.48% | |
| ₹998.40 | ₹1027.50 | ₹900.15 | ₹905.85 | -9.27% | |
| ₹999.90 | ₹1097.90 | ₹907.00 | ₹998.40 | -0.15% | |
| ₹885.00 | ₹1023.05 | ₹875.00 | ₹989.05 | +11.76% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Windlas Biotech Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Windlas Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WINDLAS across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (16.96%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 24.62 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (18.93%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (18.24% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (30.32% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (19.07x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹78.58 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (61.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Weak Earnings Growth (2.83% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Windlas Biotech Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Windlas Biotech Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Windlas Biotech LtdWindlas Biotech...Selected✓ WINDLAS • 543329 | 62.1/100 | ₹817.00₹817 | ₹1657.61₹1657.61 | 24.62Average 24.6 Average | 12.76%Average 12.76% Average | 16.96%Good 16.96% Good | 0.06Excellent 0.1 Excellent | 30.32%Excellent 30.32% Excellent | 18.24%Excellent 18.24% Excellent | 0.74% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1780.10₹1780 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6596.50₹6597 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4339.90₹4340 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1398.70₹1399 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1267.50₹1268 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2249.80₹2250 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1084.60₹1085 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2353.00₹2353 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1463.60₹1464 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5276.50₹5277 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Windlas Biotech Ltd PE Ratio History
Historical price-to-earnings ratio for WINDLAS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹28.87 | ₹795.05 | 27.5x |
| FY 2024 | ₹27.88 | ₹1041.15 | 37.3x |
| FY 2023 | ₹19.70 | ₹428.75 | 21.8x |
| FY 2022 | ₹18.58 | ₹250.10 | 13.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Windlas Biotech Ltd Dividend History
Annual cash dividends paid by WINDLAS — dividend yield 0.74%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹11.49 Cr |
| FY 2024 | ₹8.30 Cr |
| FY 2023 | ₹7.63 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Windlas Biotech Ltd Quarterly Performance
Latest quarterly metrics for WINDLAS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
18.93%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
13.67%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
18.24%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
30.32%
Compounded annual net profit growth over 5 years
Windlas Biotech Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for WINDLAS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Windlas Biotech Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Windlas Biotech Ltd (WINDLAS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Windlas Biotech Ltd
About WINDLAS (Windlas Biotech Ltd)
Windlas Biotech Ltd is a dynamic pharmaceutical company deeply rooted in innovation and quality. Specializing in contract development and manufacturing, Windlas serves as a trusted... partner for pharmaceutical companies seeking expertise in formulation development, manufacturing excellence, and comprehensive regulatory support. The company distinguishes itself through a commitment to cutting-edge technologies and a highly skilled workforce, enabling the production of complex and specialized pharmaceutical products. Windlas is driven by a desire to meet the evolving needs of its clients and contribute to advancements in healthcare, constantly striving to deliver superior products that meet stringent quality standards and regulatory requirements. With a customer-centric approach and a focus on building lasting partnerships, Windlas is positioned as a leading player in the pharmaceutical manufacturing landscape. The company's core strength lies in its diversified product portfolio and its ability to handle complex formulations. Windlas offers a broad range of manufacturing capabilities, including solid oral dosages, modified-release formulations, and specialized dosage forms. They cater to a wide array of therapeutic areas, addressing diverse healthcare needs through their innovative product offerings. Windlas emphasizes research and development, consistently seeking to enhance its manufacturing processes, expand its product range, and develop novel drug delivery systems. This commitment to continuous improvement enables them to offer customized solutions that meet the specific requirements of each client, ensuring product differentiation and market success. Windlas's reputation is built on a foundation of unwavering adherence to international quality standards and regulatory compliance. The company's state-of-the-art manufacturing facilities are equipped with the latest technologies and are meticulously maintained to ensure optimal performance and product integrity. Windlas places a strong emphasis on data integrity, transparency, and ethical business practices. By maintaining the highest standards of quality and compliance, Windlas fosters trust among its clients, regulators, and stakeholders. The company's dedication to quality and regulatory excellence is paramount, underpinning its commitment to delivering safe, effective, and reliable pharmaceutical products to patients worldwide.
Company Details
Key Leadership
Corporate Events
WINDLAS Share Price: Frequently Asked Questions
What is the current share price of Windlas Biotech Ltd?
Windlas Biotech Ltd (WINDLAS) trades at ₹817.00 on NSE and BSE. Market cap ₹1.66K (Cr). Educational data only.
What is the P/E ratio of Windlas Biotech Ltd?
Windlas Biotech Ltd has a P/E of 24.62x vs industry average 31.77x.
What is the Bull Run score for Windlas Biotech Ltd?
Windlas Biotech Ltd has a Bull Run score of 62.1/100 based on 25+ financial parameters.
Does Windlas Biotech Ltd pay dividends?
Windlas Biotech Ltd has a dividend yield of 0.74%. Past dividends don't guarantee future payments.
What is the ROE of Windlas Biotech Ltd?
Windlas Biotech Ltd has ROE of 12.76%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Windlas Biotech Ltd?
Windlas Biotech Ltd has debt-to-equity of 0.06.
Is Windlas Biotech Ltd a good investment?
Bull Run gives Windlas Biotech Ltd a score of 62.1/100. This is not investment advice — consult a SEBI-registered advisor.